2,781
Views
4
CrossRef citations to date
0
Altmetric
Review Articles

Recent progress of JAK inhibitors for hematological disorders

Pages 131-142 | Received 23 Jul 2022, Accepted 19 Oct 2022, Published online: 28 Oct 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Toshiaki Kogame, Gyohei Egawa & Kenji Kabashima. (2023) Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies. Immunological Medicine 46:3, pages 112-120.
Read now

Articles from other publishers (3)

Meenu Kesarwani, Zachary Kincaid, Mohammad Azhar, Jacob Menke, Joshua Schwieterman, Sekhu Ansari, Angela Reaves, Michael E. Deininger, Ross Levine, H. Leighton Grimes & Mohammad Azam. (2023) MAPK-negative feedback regulation confers dependence to JAK2V617F signaling. Leukemia 37:8, pages 1686-1697.
Crossref
G. Tavoletti, G. Avallone, C. Conforti, G. Roccuzzo, C. A. Maronese, M. A. Mattioli, P. Quaglino, I. Zalaudek, A. V. Marzano, S. Ribero & S. Alberti‐Violetti. (2023) Topical ruxolitinib: A new treatment for vitiligo. Journal of the European Academy of Dermatology and Venereology.
Crossref
Maria Fernanda Pessano Fialho, Evelyne Silva Brum & Sara Marchesan Oliveira. (2023) Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?. Inflammopharmacology 31:2, pages 633-651.
Crossref